Neurocrine Biosciences

Cerebral palsy is a neurodevelopmental disorder affecting movement and posture that begins in early childhood development. Dyskinesia, or uncontrollable movements, due to CP (DCP) is one of the disorder’s most disabling forms and impacts approximately 10% to 20% of those afflicted. There are currently no FDA-approved treatments for DCP, which is why clinical studies are so important. KINECT®-DCP is currently enrolling children, adolescents, and adults six to 70 years of age who have been diagnosed with DCP. Learn more about DCP symptoms, diagnosis, and clinical research in this article: https://lnkd.in/gDgtAsYP

Our CEO, Kyle W. Gano, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th at 8:15am PT, in San Francisco. Read more: https://lnkd.in/g3gukQ7h #JPM25 #JPMorganConference

Today we announced Expert Review of Endocrinology & Metabolism will publish a narrative review titled “Glucocorticoid Therapy in Classic Congenital Adrenal Hyperplasia: Traditional and New Treatment Paradigms” providing information for healthcare professionals as they navigate the evolving classic CAH therapeutic landscape. Read more: https://lnkd.in/gV8GPeRJ

Our first-in-class treatment for individuals living with classic congenital adrenal hyperplasia is now available by prescription. Read more about our treatment and the Neurocrine Access Support program: https://lnkd.in/gTtcNG2w

At Neurocrine Biosciences, our foundational work began in neuroendocrine disorders, and the approval of our treatment for classic congenital adrenal hyperplasia has been over 30 years in the making. This milestone reflects our dedication to the CAH community as we bring to market the first and only treatment specifically developed for patients living with classic CAH. Read more: https://lnkd.in/ge_hpE8Q

Our treatment for classic congenital adrenal hyperplasia has been approved by the U.S. FDA for use in adults and children, ages 4 and older. It is a first-in-class treatment developed for individuals living with classic CAH and represents a significant shift in the treatment landscape. Learn more about the impact of this approval for the CAH community. https://lnkd.in/ge_hpE8Q

We were honored to be awarded the Hall of Fame Award at the ASCP Annual Meeting. The Hall of Fame Award recognizes an ASCP Corporate Partner for distinguished service and significant contributions to the profession. For Neurocrine, this reinforces our commitment to residents in long-term care settings. 

‘Tis the season to give thanks! Our events team put on a festive, holiday lunch for Thanksgiving at our headquarters. We are grateful for the hard work and dedication of our amazing team at Neurocrine. The contributions you make positively impact patients' lives, and we are truly thankful for all that you do. 

Recognized each November, National Native American Heritage Month commemorates the culture, traditions and achievements of Indigenous People. #NativeAmericanHeritageMonth

We were thrilled to host students from Charles R. Drew University of Medicine and Science's Biomedical Sciences Enrichment Program at our headquarters in San Diego! During the visit, the students met with a panel of employees, learned about our R&D labs and explored our summer internship program. Thank you, CDU students!